MarketPulse

ZW191

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Zymeworks Inc.

Zymeworks Advances Oncology Pipeline With RAS-Targeting ADCs at AACR 2026

Zymeworks presents six ADC program updates at AACR 2026, including Phase 1 ZW191 clinical data and novel RAS-targeting platform preclinical results.
ZYMEantibody-drug conjugateoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Zymeworks Wins FDA Fast Track for Cancer Drug ZW191, Accelerating Path to Market

Zymeworks secures FDA Fast Track designation for ZW191, an ovarian cancer antibody-drug conjugate, accelerating development timelines.
ZYMEantibody-drug conjugatePhase 1 clinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Zymeworks to Showcase Pipeline Progress at Major Healthcare Conferences

Zymeworks will present clinical and preclinical data at two major healthcare investor conferences in April, including the Needham Virtual Healthcare Conference and Bloom Burton & Co. event.
ZYMEclinical datainvestor conference